Show simple item record

Overexpression of COL11A1 by Cancer-Associated Fibroblasts: Clinical Relevance of a Stromal Marker in Pancreatic Cancer

dc.contributor.authorGarcía Pravia, María del Carmen 
dc.contributor.authorGalván Hernández, José Alberto 
dc.contributor.authorGutiérrez Corral, Natalia
dc.contributor.authorSolar García, Lorena 
dc.contributor.authorGarcía Pérez, Eva
dc.contributor.authorGarcía Ocaña, Marcos 
dc.contributor.authorAmo Iribarren, Jokin del
dc.contributor.authorMenéndez Rodríguez, María Primitiva 
dc.contributor.authorGarcía García, Juan
dc.contributor.authorToyos González, Juan Ramón de los 
dc.contributor.authorSimón Buela, Laureano
dc.contributor.authorBarneo Serra, Luis
dc.identifier.citationPLoS ONE, 8(10):e78327 (2013); doi:10.1371/journal.pone.0078327spa
dc.description.abstractBackground: The collagen11A1 (COL11A1) gene is overexpressed in pancreatic cancer. The expression of COL11A1 protein could be involved in desmoplastic events in pancreatic cancer, but an antibody that specifically stains the COL11A1 protein is not currently available. Methods and findings: A total of 54 pancreatic ductal adenocarcinomas (PDAC), 23 chronic pancreatitis (CP) samples, and cultured peritumoral stromal cells of PDAC (passages 3-6) were studied. Normal human pancreas tissue samples were obtained through a cadaveric organ donation program. 1) Validation of COL11A1 gene overexpression by q-RT-PCR. Findings: the expression of COL11A1 gene is significantly increased in PDAC samples vs. normal and CP samples. 2) Analysis of COL11A1 by immunohistochemistry using highly specific anti-proCOL11A1 antibodies. Findings: anti-proCOL11A1 stains stromal cells/cancer-associated fibroblasts (CAFs) of PDAC but it does not stain chronic benign condition (chronic pancreatitis) stromal cells, epithelial cells, or normal fibroblasts. 3) Evaluation of the discrimination ability of the antibody. Findings: anti-proCOL11A1 immunostaining accurately discriminates between PDAC and CP (AUC 0.936, 95% CI 0.851, 0.981). 4) Phenotypic characterization of proCOL11A1+ stromal cells co-staining with mesenchymal, epithelial and stellate cell markers on pancreatic tissue samples and cultured peritumoral pancreatic cancer stromal cells. Findings: ProCOL11A1+ cells present co-staining with mesenchymal, stellate and epithelial markers (EMT phenotype) in different proportions. Conclusions/Significance: Detection of proCOL11A1 through immunostaining with this newly-developed antibody allows for a highly accurate distinction between PDAC and CP. Unlike other available antibodies commonly used to detect CAFs, anti-proCOL11A1 is negative in stromal cells of the normal pancreas and almost absent in benign inflammation. These results strongly suggest that proCOL11A1 is a specific marker for CAFs, and thus, antiproCOL11A1 is a powerful new tool for cancer research and clinical diagnosticseng
dc.description.sponsorshipERDF Funds from the EuropeanUnion; INNPACTO-ONCOPAN IPT-010000-2010-31 Project; FISS-09- PS09/01911 Project, Ministry of Science and Innovation, Spain; FC-11-PC10-23 Project, FICYT, Axe 1 of the 2007-2013 ERDF Operational Framework Programme of the Principality of Asturias, Spain; Progenika Biopharma, S.A.; Oncomatrix, S.L. Derio, Spain
dc.publisherPublic Library of Science (PLoS)
dc.relation.ispartofPLoS ONE, 8(10)spa
dc.rightsCC Reconocimiento - No comercial - Sin obras derivadas 3.0 España
dc.rights© 2013 C. García Pravia et al.
dc.titleOverexpression of COL11A1 by Cancer-Associated Fibroblasts: Clinical Relevance of a Stromal Marker in Pancreatic Cancereng
dc.typejournal article
dc.relation.projectIDMINECO/FISS-09- PS09/01911
dc.rights.accessRightsopen access

Files in this item


This item appears in the following Collection(s)

Show simple item record

CC Reconocimiento - No comercial - Sin obras derivadas 3.0 España
This item is protected with a Creative Commons License